SEC Company Response from Ensysce Biosciences, Inc. (ENSC, ENSCW) (CIK 0001716947) (ENSC) — Nov 28, 2017
Ensysce Biosciences, Inc. (ENSC, ENSCW) (CIK 0001716947)
Date: Nov. 28, 2017 · CIK: 0001716947 · Accession: 0001144204-17-061175
AI Filing Summary & Sentiment
File numbers found in text: 333-221330
Show Raw Text
CORRESP
1
filename1.htm
November 28, 2017
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Larry Spirgel
Re:
Leisure Acquisition Corp.
Registration Statement on Form S-1
Filed November 3, 2017, as amended
File No. 333-221330
Dear Mr. Spirgel:
Pursuant to Rule 461 of the General Rules and Regulations under
the Securities Act of 1933, as amended (the “Act”), the undersigned, for itself and the several underwriters, hereby
joins in the request of Leisure Acquisition Corp. that the effective date of the above-referenced Registration Statement be accelerated
so as to permit it to become effective at 3:00 p.m. Washington D.C. time on November 30, 2017, or as soon thereafter as practicable.
Pursuant to Rule 460 of the General Rules and Regulations under
the Act, the undersigned advises that as of the date hereof, 250 copies of the Preliminary Prospectus dated November 28, 2017
have been distributed to prospective underwriters and dealers, institutional investors, retail investors and others.
The undersigned advises that it has complied and will continue
to comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.
* * *
[signature page follows]
Very truly yours,
Morgan Stanley & Co. LLC,
as Representative of the Several Underwriters
By:
/s/ Jon Sierant
Name:
Jon Sierant
Title:
Executive Director
[Signature Page to Underwriter Acceleration
Request Letter]